Rezolute announces promotion of brian roberts, m.d. to chief medical officer

Redwood city, calif., june 01, 2022 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that brian roberts, m.d., previously senior vice president and head of clinical development, has been promoted to chief medical officer. dr. roberts joined rezolute in 2017 as vice president of clinical development and a member of the founding management team, with responsibilities that included oversight of preclinical, regulatory, and clinical operations functions.
RZLT Ratings Summary
RZLT Quant Ranking